ADHD

According to new research focused primarily on the differences and similarities between the two most common subtypes of attention deficit-hyperactivity disorder (ADHD) subtypes-ADHD-PI and ADHD-C-children with the neurological disorder could greatly benefit from individualized assessment and treatment, which means there may soon be a call to change ADHD guidelines.

One of the great thing about covering a medical conference is being able to interact with physicians and thought leaders about the hot topics in their specialty. In this video, Natasha Bergert, MD, a pediatrician from Kansas City, MO, discusses her experience at this year's AAP conference.

A recent study has found that many autistic children may be suffering from ADHD, but only some are receiving medication for their attention disorders.

College students across the US are taking the ADHD drugs recreationally because they are performing better.

Dr. Barkley speaks about treating ADHD and explores new research that is being done to better understand the condition.

Giving amphetamines to adults with ADHD can help control symptoms, but the side effects mean that some people do not manage to take them for very long.

Researchers have announced positive results from a phase II clinical study of droxidopa in combination with carbidopa in adults with ADHD.

Shire has filed lawsuits against Roxane Laboratories Inc. and Watson Laboratories Inc. for infringement of Shire patents covering Vyvanse, used to treat ADHD.

An intensive, five-week working memory training program shows promise in relieving some of the symptoms of ADHD in children.

A new study suggests "the presence of an intrinsic sleep problem specific to attention-deficit/hyperactivity disorder (ADHD) and supports the idea that children with ADHD may be chronically sleep deprived and have abnormal REM sleep."

Researchers have found that the menthol medication may be harmful for use in infants and small children due to the size of their airways.

According to the CDC, approximately 16% of boys and 8% of girls aged 5 - 17 years had ever had diagnoses of ADHD or a learning disability.

We asked our participants for their insights and opinions on the impact of social and emotional impairments associated with ADHD, considerations for the patient, consequences for the payer, and cost implications across the life span. Strattera® (atomoxetine HCl) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children age 6 and older, adolescents, and adults.

ADHD is a common presentation in all clinical settings. However, data shows that ADHD is underrecognized in adults.1 Why is this? Remember the old adage, "Out of sight, out of mind?" If ADHD is not thought of as a possibility in adult patients, is it more likely to be missed?

This article provides answers to several common questions associated with the use of Strattera® (atomoxetine HCl) to treat patients with ADHD. Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children age 6 and older, adolescents, and adults.